Hematology Genetics Panel
The Hematology Genetics Panel is a targeted Next-Generation Sequencing (NGS) assay designed to comprehensively profile the genetic landscape of both inherited and acquired (somatic) hematological disorders, bone marrow failure syndromes, and hematologic malignancies (leukemias, lymphomas, myelodysplastic syndromes). It provides essential genomic insights required for differential diagnosis, World Health Organization (WHO) subclassification, risk stratification, and precision therapeutic targeting.
Key Features & Advantages
- Precise Molecular Diagnosis: Resolves diagnostic dilemmas in complex blood disorders with overlapping clinical or morphological presentations.
- Risk Stratification & Prognostication: Classifies patients into favorable, intermediate, or adverse risk categories based on specific mutational profiles (e.g., FLT3, NPM1, TP53, ASXL1).
- Targeted Therapy Selection: Identifies actionable genomic alterations to guide targeted therapies, including tyrosine kinase inhibitors, FLT3 inhibitors, and IDH1/2 targeted agents.
- Minimal Residual Disease (MRD) Monitoring: Delivers high-sensitivity tracking of residual malignant clones following chemotherapy or hematopoietic stem cell transplantation (HSCT).
Hematology NGS Panel vs. Conventional Cytogenetics (Karyotyping / FISH)
| Feature | Hematology NGS Panel | Conventional Cytogenetics (Karyotype / FISH) |
| Analytical Resolution | Single-nucleotide variants & micro-indels | Large chromosomal structural rearrangements |
| Target Scope | Hundreds of hematology-relevant genes simultaneously | Targeted locus probes or macro-chromosomal bands |
| Cell Culture Requirement | Unnecessary (Direct DNA/RNA extraction) | Requires viable dividing cells (for karyotyping) |
| MRD Monitoring Sensitivity | Ultra-sensitive clone tracking (down to 10⁻⁵) | Limited analytical sensitivity |
| Clinical Informatics | Comprehensive variant profiling & clinical matching | Visual cytogenetic mapping / Limited data |
Key Applications
- Acute Leukemias (AML / ALL): Genomic profiling and ELN risk stratification for Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.
- Myelodysplastic Syndromes (MDS) & MPNs: Comprehensive screening for JAK2, CALR, MPL, and RNA splicing machinery mutations in MDS and Myeloproliferative Neoplasms.
- Inherited Bone Marrow Failure (IBMF): Genetic diagnosis of congenital disorders such as Fanconi Anemia, Dyskeratosis Congenita, and Diamond-Blackfan Anemia.
- Coagulation & Bleeding Disorders: Evaluating inherited thrombophilia and bleeding diatheses via targeted factor gene sequencing (e.g., F8, F9, Factor V Leiden, Prothrombin).
The Nucleus Genetics Advantage: Combining ultra-deep NGS sequencing panels customized for hematology, bioinformatics pipelines aligned with updated WHO/ELN guidelines, and expert medical genetics curation, we deliver actionable diagnostic and prognostic hematology reports.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →